Every Dravet-specific agent is an add-on to a generic backbone. Nothing here is prescribed as monotherapy, so a switching-share model describes a market that does not exist.
Dravet syndrome is a genetically defined, paediatric-onset epilepsy, and the identification funnel is the strategy. Patients reach a Dravet-specific therapy only after genetic testing confirms the diagnosis, so testing rates and referral patterns govern the size of the treatable population far more than promotion does.
Every approved Dravet agent layers onto a generic backbone and competes as an add-on. Sizing therefore runs off add-on eligibility rather than off share of a switchable pool: how many diagnosed patients remain inadequately controlled on the backbone, and how many add-ons a clinician will stack before stopping. A model that assumes patients move from one branded agent to another misreads the clinical reality, in which they accumulate rather than switch.
The pool is small and paediatric, which constrains every forecasting assumption. Numbers at this scale are too small for market-research sampling to resolve, so the funnel has to be built bottom-up and defended on its logic rather than on survey data. It also means a single change in testing or referral practice moves the forecast more than a competitive event does.
Beyond the current symptomatic agents, an antisense oligonucleotide in development targets the underlying genetic defect rather than seizure frequency. If that succeeds, the add-on model the market is built on changes shape, and a forecast that assumes the current structure persists will need rebuilding.
AXLRx Dravet reports build the genetic-identification funnel end to end and size on add-on eligibility.
US incidence 1 in 15,700, de novo SCN1A genetics, and one of the highest SUDEP rates documented in epilepsy.
Fintepla's list price runs roughly 3x Epidiolex, and payer scrutiny turns on high WAC against a small, severe paediatric population.
Fenfluramine leads on efficacy, cannabidiol anchors the lower-cost branded option, and stiripentol holds the adjunct niche.
GCC Dravet prescribing runs opposite the US and EU hierarchy. Cannabidiol is de-facto inaccessible under narcotics law, so stiripentol is the specialist standard of care.
The 1,400–2,000-patient refractory Dravet cohort is the opening. REMS-free cardiac safety and a 45%-Medicaid access plan decide who reaches it.
600-800 estimated GCC Dravet patients, fewer than 200 SCN1A-confirmed. A 200-400 near-term addressable cohort sits within that confirmed subset.
NICE recommended both Dravet therapies through standard Technology Appraisal, not the ultra-rare HST route. This covers what the Fintepla Cardiac Monitoring Scheme costs the NHS, and why the UK treatment algorithm is now closed to new entrants without a significant clinical edge.
SCN1A molecular confirmation gap, the cannabidiol regulatory restriction, and the stiripentol-backbone standard of care across GCC paediatric neurology.
A five-institution Saudi consortium across Riyadh, Jeddah and Dammam tracked 44 Dravet patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it.
GCC Dravet pricing is an import-cost problem, not a rebate negotiation. Cannabidiol's Schedule-1-equivalent narcotics classification adds USD 10-15K in compassionate-programme cost plus SAR 5-8K in import logistics, while stiripentol's non-narcotic status keeps it at SAR 30-50K through standard hospital import.
Both existing Dravet therapies cleared NICE's standard Technology Appraisal, not the ultra-rare Highly Specialised Technology route. A new entrant's WAC, PAS, and stakeholder-engagement calendar all need to be built against that lower cost-effectiveness bar, with soticlestat's 2026-27 appraisal setting the clock.
US Dravet incidence of 1 in 15,700 births is consistent with the Dravet Syndrome Foundation's 6,000-8,000 prevalence estimate. Only 35-40% of that population, 1,400-2,000 patients, remains inadequately controlled on today's two branded agents.
600-900 UK Dravet patients remain uncontrolled on CBD plus fenfluramine. This weighs the cardiac-monitoring burden a REMS-free agent could remove against the soticlestat clock competing for the same refractory population.
6,000-8,000 US Dravet patients, roughly three-quarters SCN1A-confirmed. 35-40% are still inadequately controlled on cannabidiol plus fenfluramine, the population any new agent must actually reach.
2,000-2,500 UK Dravet patients, of whom 400-500 are SCN1A-confirmed in genetic registries. 600-900 remain inadequately controlled on cannabidiol plus fenfluramine.
The UK's NICE-commissioned Dravet algorithm manages an estimated 2,000-2,500 patients on cannabidiol and fenfluramine. The NHS genetic testing registry logs only 400-500 molecularly SCN1A-confirmed cases — a registry-scope gap, not a population contradiction.
GCC Dravet prevalence is estimated at 600-800 patients, but fewer than 200 are molecularly SCN1A-confirmed. The 200-400 figure used in launch planning is a distinct near-term actionable tier, not a fourth competing total.
The NHS runs the most treatment-advanced Dravet pathway in Europe. Free SCN1A testing on GMS, a NICE-defined CBD-then-fenfluramine algorithm, and 25 paediatric epilepsy HSS centres underpin it.
The binding constraint for a new Dravet agent in the GCC is regulatory classification, not efficacy. Any agent must clear the SFDA Controlled Drug Board as non-controlled, because CBD-class compounds are permanently excluded.
Fintepla's weight-based list price runs roughly 3x Epidiolex. Payers work that gap through step-edit design layered on Part D pharmacy-benefit routing, and no generic cannabidiol reaches the US market before the late 2030s.
Six NHS centres concentrate the UK's refractory Dravet syndrome cohort. Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds and Newcastle. The British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission, and that institutional network is what this workbook sizes first, not a roster of named physicians.
Both NHS-commissioned Dravet therapies cleared NICE's standard £20,000-30,000/QALY bar, not the ultra-rare HST threshold. A new entrant is held to the same bar the incumbents already cleared, and total NHS Dravet spend still runs a modest £9-16M.
The most effective Dravet agent is the least accessible in the GCC. Cannabidiol's Schedule-1-equivalent narcotics classification caps exceptional-import approval at 35-40%.
Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy.
Dravet syndrome is a rare paediatric-onset developmental and epileptic encephalopathy. US incidence runs about 1 in 15,700 births, consistent with a Dravet Syndrome Foundation registry estimate of roughly 6,000 to 8,000 US patients. It carries one of the highest syndrome-specific SUDEP rates in epilepsy, 9.32 per 1,000 person-years, with a median age at death of 7 years. True prevalence exceeds the molecularly confirmed count everywhere: the UK has an estimated 2,000 to 2,500 patients but only 400 to 500 SCN1A-confirmed, and the GCC 600 to 800 with fewer than 200 confirmed.
Diagnosis combines a characteristic seizure history with genetic confirmation. Onset falls in the first year of life, with febrile seizures and at least two seizures before 12 months, and a likely-pathogenic de novo SCN1A mutation is found in roughly 75% of clinical cases. SCN1A genetic testing defines the addressable funnel: the UK NHS Genomic Medicine Service offers free testing reaching about 75% molecular confirmation, whereas the GCC confirms fewer than 200 patients across only 5 to 6 genetic centres. The genetic-confirmation step, not raw prevalence, gates the market.
Three Dravet-specific agents sit on a generic valproate and clobazam backbone. Stiripentol (Diacomit, Biocodex), a GABA-A modulator, was approved in August 2018 as an adjunct and posted a 71% responder rate in STICLO. Cannabidiol (Epidiolex, Jazz Pharmaceuticals), a plant-derived oral CBD, was approved in June 2018 and showed a 38.9% convulsive-seizure reduction in GWPCARE1. Fenfluramine (Fintepla, UCB), a low-dose serotonin-releasing agent, was approved in June 2020 with a REMS cardiac-monitoring requirement and posted a 62.3% greater seizure reduction versus placebo in Study 1.
The commercial pool is the molecularly confirmed subset, not epidemiological prevalence, so AXLRx sizes from the genetic-diagnosis funnel outward. We start with incidence-derived prevalence, then apply market-specific SCN1A confirmation rates: about 75% where the NHS Genomic Medicine Service funds free testing, under 30% across the GCC's 5 to 6 genetic centres. That gap is the growth lever. Earlier genetic testing in early-life epilepsy converts undiagnosed febrile-seizure children into an identified, addressable pool, expanding the numerator faster than raw prevalence moves. A patient-flow model that segments prevalence down to the SCN1A-confirmed refractory cohort, rather than treating total prevalence as addressable, is the honest basis for any Dravet forecast.
Every Dravet-specific agent layers onto a generic valproate and clobazam backbone and competes as an add-on, never as monotherapy, so switching-share models mislead. AXLRx sizes by add-on eligibility: within the SCN1A-diagnosed funnel, the addressable pool is the refractory subset inadequately controlled on the existing regimen, an estimated 1,400 to 2,000 of 6,000 to 8,000 US patients on cannabidiol plus fenfluramine. We then model combination sequencing, not displacement, asking where a new agent slots against the entrenched cannabidiol-plus-fenfluramine background and what incremental seizure-reduction bar, roughly 40%, it must clear. Pediatric weight-based dosing sets per-patient value, so the forecast becomes eligibility times sequencing share times weight-adjusted price.
Dravet is a small paediatric-onset pool, and that shapes every forecasting assumption. With roughly 6,000 to 8,000 US, 2,000 to 2,500 UK, and 600 to 800 GCC patients, the numbers are too small for market-share smoothing, so AXLRx forecasts patient-by-patient off named specialist centres rather than territory averages. Refractory care concentrates: six NHS centres in the UK, a five-institution Saudi consortium in the GCC, so a KOL-anchored, site-level build beats top-down penetration curves. Paediatric onset means the pool refreshes through incident births rather than a large prevalent backlog, and weight-based dosing, about $96,000 a year for fenfluramine at the high end, makes per-patient value and access, not volume, the commercial battleground.
Today's approved agents are symptomatic, layering seizure control onto the backbone, but the pipeline threatens that model. Zorevunersen (STK-001, Stoke Therapeutics), an antisense oligonucleotide, targets the underlying SCN1A haploinsufficiency rather than symptoms, and a disease-modifying mechanism would reset the value conversation from incremental seizure reduction to trajectory change. AXLRx models this as a scenario overlay on the symptomatic forecast: a genetic-diagnosis funnel that identifies patients earlier becomes even more valuable when the intervention modifies disease, since earlier confirmation widens the treatable window. Soticlestat (Takeda/Ovid), studied in ELEKTRA with no cardiac-monitoring requirement, is the nearer-term symptomatic benchmark. A credible forecast prices both the add-on base case and the ASO disruption case, not one alone.
Every answer above rests on one thesis: in Dravet, the genetic-identification funnel is the strategy, not broad promotion. AXLRx builds that funnel end to end, disease landscape, competitive intelligence, and payer briefs across the US, UK, and GCC; market-sizing and patient-flow models that segment prevalence down to the SCN1A-confirmed refractory cohort; KOL mapping of the concentrated paediatric-neurology centres; and launch-readiness and HTA-strategy work benchmarked against the approaching soticlestat and zorevunersen milestones. Each figure is live-sourced and independently verified before delivery.